A report released by the Royal College of Surgeons shows more men are getting an appropriate level of treatment, but issues with late diagnosis persist and uptake of mpMRI has been patchy. However, a pilot scheme also announced today offers a promising step forward.
Our new precision medicine research programme aims to tailor treatments based on the genetic make-up of a man’s prostate cancer. The results could extend the lives of more than 9,000 men with advanced disease every year in the UK.
Plans to rollout mpMRI scans before a first biopsy for all UK men suspected of prostate cancer are under threat, as long-term vacancies and increasing demand put a strain on the NHS's radiology services.
A type of radiotherapy that shapes radiation beams to tumors has grabbed headlines today. But more in-depth trials, already underway, are needed to give a clearer picture of the benefit for men.
A new study suggests olaparib could boost the efficacy of treatment for earlier-stage prostate cancer, after discovering how it can block the repair of DNA in cancer cells no matter what kind of the disease they have.
Prostate Cancer UK is urging health authorities to improve access to prostatectomy treatment for men in Northern Ireland, after reports of delays and inadequate support for patients being flown to England for surgery.
The hot summer weather can exacerbate the fatigue experienced by many men undergoing prostate cancer treatment. So our Specialist Nurse, Meg Burgess, explains what things you can do to help manage the discomfort – including the merits of a Mediterranean-style siesta.
Researchers at the Institute of Cancer Research have created a powerful new three-in-one blood test, which could help doctors monitor whether a treatment is working and how a man's cancer is responding. We examine the results and find out why it's another step in the creation of targeted treatments for prostate cancer.
Announced by researchers at a cancer conference in Chicago, the new findings show earlier and combined use of existing treatments can have a significant impact on advanced disease, but questions remain about its suitability for all men.
New research funded by Prostate Cancer UK has discovered a blood test that can predict which men's cancer won't respond to certain hormone therapy, so they can pick the treatment that works for them while saving the NHS potentially huge sums on otherwise wasted drugs.